Evident Technologies Biotin EviFluors, De Novo Pharmaceuticals and Peakdale Molecular s Peakexplorer, and TSG Partners Market Research Reports | GenomeWeb

Evident Technologies announced last week that it has begun commercial production of Biotin EviFluors, its first biotinylated quantum dot fluorophores.

EviFluor offers advantages over traditional fluorophores, including brighter emission and greater stability, for applications such as cell biology, drug discovery, and cancer research, the company said. The product is available in wavelengths from blue to infrared.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.